Charlottetown-based biotechnology company announces the appointment of Meletios Roussis as Chief Operating Officer
Charlottetown, PE – Somru BioScience Inc., a leading biotechnology company based in Charlottetown, PEI, dedicated to developing breakthrough antibody technology for research, diagnostic and therapeutic applications, has announced the appointment of Meletios Roussis as Chief Operating Officer, effective November 14, 2022.
Mr. Roussis has over 10 years of experience in the biotech industry with a focus on business development to expand into new markets and the acquisition of new clients, leading teams in regulated bioanalytical programs, process optimization, and implementation of new technologies. He has developed talented scientific teams and mentored employees to reach their full potential.
A new role at Somru, as Chief Operating Officer, Mr. Roussis will report to CEO Mohammed Moin and lead the large molecule bioanalytical service business of Somru. Mr. Roussis will add oversight to Somru’s global business operations including the development of growth strategies across a number of geographic regions and enhancement of Somru’s cloud based Aegryris™ software suite and connectivity with its clients, enhancing the client experience.
“Meletios brings a decade of diverse experience in research and development, scaling businesses, and blending entrepreneurial spirit with technical aptitude,” said CEO Mohammad Moin. “We are thrilled to have him join the team at Somru”.
“I look forward to building on Somru’s biosimilar experience to engage with more clients, expanding services into novel therapeutics and vaccines. Somru has provided bespoke renowned client service via its proprietary software and automation systems, and I look forward to sharing and expanding that experience with our present and future clients” said Mr. Roussis.
Somru BioScience Inc.
About Somru BioScience Inc.
Somru BioScience Inc. is an innovative biotechnology company based out of Prince Edward Island, Canada. Somru has developed a portfolio of reagents, ELISA kits, innovative biosimilar comparability tools and a cloud based Aegryris™ software suite to enable companies to significantly reduce the cost and timeline for biosimilar development. Somru technologies reduce early development risk by identifying clinically meaningful differences prior to running expensive clinical trials. The company has customers throughout North and South America, Europe, Australia, and Asia.